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http://dxObjective: Group IIa secretory phospholipase A2 (sPLA2 IIa) plays a role in the malignant potential of several
epithelial cancers. Nuclear factor kappa B (NF-kB) regulates cancer cell growth and is modulated by phospho-
lipase activity in many cancer cells. We hypothesized that knockdown of sPLA2 in lung cancer cells would
reduce cell proliferation and NF-kB activity in vitro and attenuate tumor growth in vivo.
Methods: Two human non–small cell lung cancer cell lines (A549 and H358) were transduced with short hairpin
RNA targeting sPLA2 group IIa. Quantitative reverse transcriptase-polymerase chain reaction and immunoblot-
ting confirmed knockdown of sPLA2 IIa messenger RNA and protein, respectively. Cell proliferation was eval-
uated by the 5-bromo-20-deoxyuridine DNA labeling assay. NF-kB phosphorylation was assayed by western
blot. 1 3 106 of A549 or A549 sPLA2 knockdown cells were injected into the left flanks of nude mice (aged
6 to 8 weeks). Tumors were followed for 23 days, then removed and stained with hematoxylin and eosin, stained
with Ki-67, and analyzed for sPLA2 IIa messenger RNA expression.
Results: sPLA2 knockdown reduced NF-kB phosphorylation and tumor growth in vivo. A549 wild-type tumors
grew twice as fast as knockdown tumors. Ki-67 staining was more prominent throughout the wild-type tumors
compared with knockdown tumors. Explanted knockdown tumors maintained lower sPLA2 levels compared
with wild-type, confirmed by reverse transcriptase-polymerase chain reaction.
Conclusions: Knockdown of sPLA2 IIa suppresses lung cancer growth in part by attenuating NF-kB activity.
These findings justify further investigation into the cellular mechanisms of sPLA2 in lung cancer and its poten-
tial role as a therapeutic target. (J Thorac Cardiovasc Surg 2012;144:1185-91)E
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SGroup IIa secretory phospholipase A2 (sPLA2 IIa) has
recently come to light as an important growth-regulating
molecule in several malignancies, including esophageal,
prostate, and lung cancer.1-4 We previously demonstrated
that inhibition of group IIa sPLA2 decreased intercellular
adhesion molecule-1 (ICAM-1) associated invasion of
lung cancer cells in vitro4; however, the role of the enzyme
in lung cancer cell growth has yet to be fully explored.
Phospholipase A2 (PLA2) enzymes catalyze arachidonic
acid release from cell membranes, a rate-limiting step in the
pathway leading to the production of tumor-stimulating ei-
cosanoids such as prostaglandins.5-7 PLA2 activity is
upregulated in some lung cancers8 and there is decreased
lung tumor formation in PLA2 knockout mice.9 Withine Section of General Thoracic Surgery, Division of Cardiothoracic Surgery,
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The Journal of Thoracic and Carthe family of PLA2 enzymes is the subgroup of secretory
PLA2s (sPLA2s). sPLA2 IIa is secreted by a number of
cell-types, including epithelial cells of the human airway.10
In addition to its phospholipase enzymatic activity, sPLA2
IIa has been reported to signal as a ligand through receptors
that modulate cancer cell proliferation, including the epi-
dermal growth factor receptor, leading to downstream acti-
vation of AKT and extracellular signal-regulated protein
kinase 1/2 pathways.11,12 Paracrine interaction between
sPLA2 IIa and human lung macrophages also results in
the release of growth factors that promote proliferation
and angiogenesis.13
Nuclear factor kappa-B (NF-kB) transcription factors fa-
cilitate cell growth by stimulating proliferation genes. In
cancer cells, breakdown of NF-kB feedback loops or consti-
tutive activation of NF- kB leads to increased proliferation,
angiogenesis, and metastasis.14 NF-kB target genes include
components of the arachidonic acid pathway15 as well as
proteins that increase the transcription of growth factors.16
Evidence suggests that sPLA2 IIa modulates NF-kB, as
ICAM-1 and sPLA2 IIa, both NF-kB target genes, are
downregulated when sPLA2 IIa is inhibited.3,4,12
We hypothesize that the knockdown of sPLA2 in lung
cancer cells will reduce cell proliferation and that this effect
will correlate with decreased NF-kB activity. Furthermore,
we propose sPLA2 knockdown in lung cancer cells will at-
tenuate tumor growth in vivo.diovascular Surgery c Volume 144, Number 5 1185
Abbreviations and Acronyms
sPLA IIA ¼ group IIa secretory phospholipase A2
NF-kB ¼ nuclear factor kappa B
ICAM-1 ¼ intercellular adhesion molecule-1
PLA2 ¼ phospholipase A2
FBS ¼ fetal bovine serum
TNF-a ¼ tumor necrosis factor-a
PBS ¼ phosphate buffered saline
shRNA ¼ short-hairpin RNA
RT-PCR ¼ reverse transcriptase-polymerase chain
reaction
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SMATERIALS AND METHODS
Cells and Reagents
A549 cells were obtained from American Type Culture Collection
(Manassas, Va). H358 cells were a gift from Kim O’Neill, PhD (Brigham
Young University, Provo, Utah). Cells were maintained in a humidified at-
mospherewith 5% carbon dioxide using Ham’s F-12media (Cellgro, Man-
assas, Va) or Roswell Park Memorial Institute Media 1640 (Gibco, Grand
Island, NY), respectively, with 10% fetal bovine serum (FBS). Tumor ne-
crosis factor-alpha (TNF-a) (Sigma-Aldrich, St Louis, Mo) was used to in-
duce NF-kB activation. It was dissolved in phosphate buffered saline (PBS)
and used at a concentration of 20 ng/mL. Antibodies for phosphorylated
and total NF-kB and glyceraldehyde 3-phosphate dehydrogenase were ob-
tained from Cell Signaling Technology, Inc (Beverly, Mass). Antibody for
sPLA2 IIa was obtained from Abcam (Cambridge, Mass).
Short-Hairpin RNA (shRNA) Vectors
pLKO.1 puro lentiviral vectors containing non-targeted shRNA and 4
distinct shRNA sequences targeting sPLA2 IIa were purchased from
Sigma-Aldrich. The sequences and preparation of infectious lentiviral con-
structs are the same as previously described.2
Quantitative Reverse Transcriptase-Polymerase
Chain Reaction (RT-PCR)
Cells were plated in 12-well plates at a density of 13 106 in full media
for 24 hours, then serum-starved (0.5% FBS) for 24 hours before lysis. Xe-
nograft tumors stabilized in RNAlater (Qiagen, Germantown, Md) were
disrupted by sonication for RNA preparation. Preparation of RNAwas per-
formed using the Qiagen RNeasy Mini Kit according to the manufacturer’s
protocol. Complementary DNA was synthesized using Bio-Rad iScript
(Hercules, Calif). RT-PCR was performed using Applied Biosystems
Sybr Green Master Mix (Carlsbad, Calif). The primer sequences used are
as follows: sPLA2 IIa (forward), CCC-TCC-TAC-TGT-TGG-CAG-TGA-
T; sPLA2 IIa (reverse), CCT-GTC-GTC-AAC-TTG-ATC-ATT-CTG; glyc-
eraldehyde 3-phosphate dehydrogenase (forward), CCT-GCA-CCA-CCA-
ACT-GCT-TAG; and glyceraldehyde 3-phosphate dehydrogenase (re-
verse), TGA-GTC-CTT-CCA-CGA-TAC-CAA. Denaturation (95C for
15 seconds), annealing (52C for 30 seconds), and elongation (72C for
30 seconds) were repeated for 40 cycles, flanked by a 10-minute denatur-
ation and 5-minute elongation step. Data was analyzed by the delta delta
cycle threshold method.
Western Blotting
Cells were plated on 6-well plates at a density of 3 3 106 in full media
for 24 hours, then serum-starved (0.5% FBS) for 24 hours, then treated.
Cells were stimulated with or without TNF-a (20 ng/mL) for 4 hours,
then lysed with Laemelli buffer under reducing conditions. Time trials1186 The Journal of Thoracic and Cardiovascular Surwith TNF-a identified sustained changes in NF-kB activation at this time
point (data not shown). Proteins were separated using sodium dodecyl
sulfate polyacrylamide gel electrophoresis techniques and transferred to
nitrocellulose membranes. Membranes were blocked in 5% nonfat milk
in 1 3 PBS, 0.1% Tween-20 (Sigma-Aldrich). Primary antibodies were
dissolved in 5% bovine serum albumin (Sigma-Aldrich), 1 3 PBS,
0.1% Tween-20. Secondary antibodies were prepared in 5% nonfat milk
in 1 3 PBS, 0.1% Tween-20. The protein of interest was developed using
Pierce ECL Chemiluminescent (Thermo Fisher Scientific, Inc, Rockford,
Ill). Densitometric analysis was performed using ImageJ Software
(National Institutes of Health, Bethesda, Md).
Cell Proliferation Assay
Cell proliferation was evaluated by the 5-bromo-20-deoxyuridine DNA
labeling assay according to manufacturer instructions (Roche Applied Sci-
ence, Indianapolis, Ind).
Xenograft Experiment
All xenograft experiments were performed under a protocol approved
by the University of Colorado Institutional Animal Care and Use Commit-
tee. Male nude mice aged 6 weeks were purchased from Harlan Laborato-
ries (Indianapolis, Ind) and quarantined for 2 weeks. At age 8 weeks the
mice were injected into their left flanks with 1 3 106 cells in 100 mL
PBS. Flank tumors were measured every 2 to 3 days using digital calipers
and volumewas calculated by multiplying height3 length3width. Xeno-
graft tumors were removed en bloc and a portion from each tumor was pre-
served in 4% formalin in PBS and RNAlater. RT-PCR of tumor tissue
homogenate was used to examine sPLA2 IIa messenger RNA (mRNA)
as described above. Tumors preserved in formalin were paraffin embedded;
cut onto slides; and stained with hematoxylin and eosin, and for Ki-67. His-
tology was reviewed by a pathologist blinded to the study.
Statistical Analysis
All data distributions were inspected before statistical analysis. Student
t test was performed for 2 group comparisons, and analysis of variance test
was performedwhen comparing 3 or more groups. Nomultiple comparison
was conducted. StatView V5.0 (1998; SAS Institute Inc, Cary, NC) was
used for all statistical analysis.
RESULTS
Knockdown of sPLA2 IIa in Non–Small Cell Lung
Cancer Cells
A549 and H358 cells were stably transduced with green
fluorescent protein-tagged lentiviral vector particles to con-
firm efficacy of technique and optimal concentration of par-
ticles for transduction (Figure 1, A). Cells were then
transduced with lentiviral particles containing shRNA for
sPLA2 IIa, or nontargeted shRNA as a control. Selection
for transduced cells was with puromycin antibiotic. A kill
curve was performed in both cell lines to determine a puro-
mycin concentration of 2 mg/mL for selection (data not
shown). Four distinct short hairpin sequences targeting
sPLA2 IIa were used and examined for knockdown of
sPLA2 IIa bothmRNAand protein expression. RT-PCR con-
firmed decreased mRNAwith all sequences, from S1 to S4
(Figure 1, B). Western blot for sPLA2 IIa revealed sequence
S2 resulted in the most robust knockdown of protein expres-
sion (Figure 1, C). Similar results were obtained in H358
cells, although only data for A549 cells is shown. All subse-
quent experiments used A549 and H358 cells transducedgery c November 2012
A549 cells
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FIGURE 1. Short-hairpin RNA (shRNA) sequence S2 obtains most robust knockdown of secretory phospholipase A2 (sPLA2) group IIa messenger RNA
and protein. A549 and H358 cells were stably transduced with green fluorescent protein (GFP)-tagged lentiviral vector particles, (A) to determine the op-
timal conditions for transduction, before transducing cells with vector particles containing nontargeted shRNA as a control, or shRNA targeting sPLA2 IIa.
Growth selection for transduced cells was with puromycin. Four distinct shRNA sequences (S1 to S4) targeting group IIa sPLA2 were used to create 4 dif-
ferent knockdown cell lines. B, Knockdown was confirmed by messenger RNA and (C) protein analysis. The most robust knockdown in protein was with
sequence S2. RT-PCR, Reverse-transcription polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Swith sequence S2 shRNA targeting sPLA2 IIa (A549 S2,
H358 S2), or nontargeted shRNA (A549 NT, H358 NT),
comparedwith nontransducedwild-typeA549orH358 cells.
sPLA2 IIa Knockdown Decreases Proliferation in
Non–Small Cell Lung Cancer Cells
Stable knockdown of sPLA2 IIa mRNA compared with
both wild-type controls and nontargeted controls was con-
firmed over several cell passages using RT-PCR (Figure 2,
top panels). Proliferation studies using the 5-bromo-20-de-
oxyuridine assay were performed with the same passages
of cells. Results showed a stable reduction by approximately
40% to 50% in the growth rate of both A549 and H358
knockdown cells compared with both control groups
(Figure 2, bottom panels). This is consistent with our finding
during cell culture that double the concentration of S2 cellsThe Journal of Thoracic and Carcompared with nontargeted or wild-type cells were required
for the cells to reach confluence at the same time.
sPLA2 IIa Knockdown Decreases NF-kB Activity
We have previously demonstrated that pharmacologic
sPLA2 IIa inhibition decreases NF-kB activity leading to
apoptosis in non–small cell lung cancer cells.17 Results
from knockdown experiments are similar, because NF-kB
phosphorylation in S2 cells is significantly decreased com-
pared with nontargeted or wild-type cells (Figure 3).
sPLA2 IIa Knockdown Decreases Non–Small Cell
Lung Cancer Growth In Vivo
Xenografts of AS2 cells grew significantly slower than
wild-type cells (Figure 4, A and B), with wild-type tumors
growing to double the volume of knockdown tumors atdiovascular Surgery c Volume 144, Number 5 1187
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FIGURE 2. Secretory phospholipase A2 group-IIa (sPLA2 IIa) knockdown is stable over several cell passages with corresponding persistent decrease in
growth rate of lung cancer cells. Top panels, Quantitative reverse-transcription polymerase chain reaction confirms decreased messenger RNA (mRNA) over
several cell passages 1 through 7. Bottom panels, Analysis of proliferation using the same cell passages 1 through 7 shows a stable reduction in the growth
rate of both A549 and H358 knockdown cells. Controls for the experiments are wild-type cells and vector controls (NT). Data are presented as mean 
standard error of the mean; n ¼ 3-5 performed in triplicate. *P<.05.
FIGURE 3. Secretory phospholipase A2 group IIa (sPLA2 IIa) knock-
down decreases nuclear factor-kB (NF-kB) activity. Tumor necrosis fac-
tor-a (TNF-a) induces NF-kB phosphorylation in A549 cells, vector
control cells (ANT) and knockdown cells (AS2), though significantly less
in the knockdown cells. Representative western blot of a single experiment
is shown with a graph of densitometric analysis of cumulative experiments
below (mean  standard error of the mean; n ¼ 5 per group). Pharmaco-
logic sPLA2 IIa inhibition in lung cancer cells results in a similar decrease
in NF-kB phosphorylation (data not shown). *P<.05.
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SPostinjection Day 23. Histology from tumors revealed large
areas of necrosis characteristic of rapid growth (Figure 4,
C). Tumors were also stained with Ki-67, a marker of pro-
liferation. Wild-type tumors had more Ki-67 staining and
the location of the staining was throughout the tumor, com-
pared with knockdown tumors where the staining was more
visible at the periphery. Analysis of sPLA2 mRNA expres-
sion in xenograft tumors confirmed persistent decrease in
sPLA2 mRNA in knockdown tumors compared with wild-
type tumors (Figure 5).DISCUSSION
Ours is the first study that demonstrates decreased tumor
growth in vivowith knockdown of sPLA2 IIa mRNA. These
data support a role for sPLA2 IIa in the growth of non–small
cell lung cancer and bolster evidence for its relevance as
a therapeutic target. Previous studies have reported antimi-
togenic effects of sPLA2 IIa pharmacologic inhibition and
our results using RNA interference support those findings.
These data are compelling from both a mechanistic and
therapeutic perspective. RNA interference is a potential
therapeutic tool. Delivering small interfering RNAs to solid
tumors has been reported via intratumoral injection,18 as
well as via intravenous delivery. A recent study19 showed
that systemically administered small interfering RNA nano-
particles successfully target human cancer cells and reduce
target protein levels in tumor tissue. Given that short hairpin
knockdown of sPLA2 IIa mRNA slows tumor growth,gery c November 2012
FIGURE 4. Secretory phospholipase A2 group IIa knockdown decreases lung cancer cell growth in vivo. A549 and knockdown cells were injected into the
left flanks for nude mice and tumor size was serially measured until postinjection day 23. A, Representative photograph of xenograft tumors in situ dem-
onstrating increased A549 tumor size compared with the knockdown tumors. B, Volume of the tumors over time shows significant growth retardation in the
knockdown cells (AS2) compared with A549 cells (mean standard error of the mean; n¼ 5) per group. C, Representative histology from knockdown and
wild-type tumors exhibit large areas of necrosis representative of fast growth. Wild-type tumors demonstrate increased Ki-67 staining in the compared with
more peripheral and less concentrated staining in the knockdown tumors.
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Stargeted RNA interference of sPLA2 IIa may have a thera-
peutic application in the treatment of lung cancer.
We recently examined the relationship between sPLA2
IIa inhibition and cell survival signaling associated with
p38 mitogen-activated protein kinase, extracellular signal-
regulated protein kinase 1/2 pathways, AKT, and NF-kB ac-
tivity in lung cancer cells.17 The results demonstrated
a dominant link between NF-kB, sPLA2 IIa, and cell viabil-
ity. Our study shows that knockdown of sPLA2 IIa de-
creases NF-kB activity, further supporting the hypothesis
of a role for sPLA2 IIa and NF-kB interaction that slows tu-
mor growth.
These data suggest not only potential for sPLA2 IIa as
a therapeutic target, but also several mechanisms that canThe Journal of Thoracic and Carbe examined to better understand the unique role of
sPLA2 IIa in lung tumor growth.We have thus far examined
only growth factor-independent mitogenic signaling, but
cancer cells can acquire the capability to sustain prolifera-
tive signaling by producing growth factors as well as corre-
sponding growth factor receptors.20 Targeting sPLA2 IIa
may exploit its relationship with NF-kB because NF-kB tar-
get genes include transcription factors for a number of
growth factors such as vascular endothelial growth factor,
fibroblast growth factor, and platelet-derived growth factor,
which have been linked to promoting cancer cell growth, tu-
mor stroma development, and angiogenesis.20-22
Phospholipase enzymes catalyze the first rate-limiting
step in the production of eicosanoids. In lung cancerdiovascular Surgery c Volume 144, Number 5 1189
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FIGURE 5. Secretory phospholipase A2 group IIa (sPLA2 IIa) messenger
RNA (mRNA) remains decreased in knockdown tumors compared with
wild-type tumors. Reverse transcriptase-polymerase chain reaction of tu-
mor homogenates shows that wild-type tumors had more than double the
amount of sPLA2 IIa mRNA compared with knockdown tumors. Average
of DDCt for all 5 knockdown tumors was compared with the average of
DDCt for all 5 wild-type tumors. Results presented as mean standard er-
ror of the mean; n ¼ 3 performed in triplicate.
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tumor growth.5-7 sPLA2 IIa inhibition may modulate
eicosanoid production in lung cancer cells. Future research
aims include eicosanoid-dependent versus eicosanoid-
independent mechanisms of growth mediated by sPLA2 IIa.
Another hallmark of cancer are its activating mecha-
nisms of invasion and metastasis.23 Previous work has
shown that pharmacologic inhibition of sPLA2 IIA reduces
ICAM-1 associated invasion in vitro.4 On review of the his-
tology, intravascular invasion was noted in the wild-type tu-
mors but not in the knockdown tumors. Further studies will
better address the role of sPLA2 IIa in metastatic disease
in vivo.
Our study has several limitations. We compared wild-
type and sPLA2 knockdown tumor growth without compar-
ing these to a vector (ie, nontargeted) control group.
Expanding the in vivo studies to include multiple cell lines
and vector controls are goals for future studies. After 3
weeks of growth the knockdown tumors had persistent
low levels of sPLA2 mRNA and peripheral Ki-67 staining.
We were unable to detect the presence of the vector or cor-
relate Ki-67 with sPLA2 expression. Future experiments
will aim to correlate sPLA2 expression with Ki-67 staining,
or proliferative potential in vivo.
CONCLUSIONS
sPLA2 IIa plays a significant role in modulating lung
cancer cell growth. The relevance of sPLA2 IIa as a thera-
peutic target has expanding potential and studies investigat-
ing the expression of sPLA2 IIa in human tumor tissue are
ongoing. Interestingly, group IIa sPLA2 inhibitors are
available in both oral and intravenous formulations, having
been tested in clinical trials for inflammatory disease with
few adverse side effects noted in these study populations.241190 The Journal of Thoracic and Cardiovascular SurThe results of our study strongly support the rationale for
investigating the efficacy of these agents in malignancy.
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vice, as well as Daniel T. Merrick, MD, and Francisco G. La Rosa,
MD, University of Colorado, for their assistance in interpreting the
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SDiscussion
Dr Thomas Waddell (Toronto, Ontario, Canada). Secretory
phospholipase A2 (sPLA2), as you mentioned, is part of a family
that is involved in generating products of arachidonic acid down-
stream. And although a role in host defense, inflammatory injury,
and atherosclerosis has been understood for many years, a specific
role for cancer has been largely overlooked. So congratulations to
you and your supervisor for a foray into this field.
You have convinced me that knockdown of sPLA2 results in in-
hibition of nuclear factor kappa B signaling and, as a result, prolif-
eration in vitro and in vivo. I have some technical questions and 1
overview question. You show nicely that the S2 short-hairpin RNA
was the best 1 of the 3 that you examined in terms of its effect on
reducing phospholipase A2 (PLA2), but what about off-target ef-
fects? Is it the most specific molecule? Were there actually any ef-
fects on other members of the PLA2 family?
Dr Jessica Yu. We actually have looked at 1 other family
member, group IV cystosolic PLA2, and the level does not
change substantially with sPLA2 inhibition. I have not yet looked
at cytosolic phospholipases A2 in the knockdown. There are 12
groups of PLA2 enzymes, so it would be difficult to investigate
all of them.
DrWaddell.On to the next question. I would like to come back
to the data you presented about Ki67 being positive on the perim-
eter of the tumors growing in vivo. Do you have any speculation as
to why that finding might have been seen?
Dr Yu. That is an interesting question with several possibili-
ties. Cells in the dish are under constant selection with puromy-
cin, and when we inject the tumor cells into mice, they are no
longer in a selected environment. I did batch selection, not clonalThe Journal of Thoracic and Carselection, and was actually surprised to see a difference with that
technique.
So maybe the perimeter is where we see proliferation of cells
that are no longer being selected for. Another possibility is, of
course, interactions with the microenvironment at the perimeter
that stimulate proliferation. Microenvironment interaction would
be another interesting study.
Dr Waddell. I think both are good. A third I would suggest
thinking about is the hypoxic environment at the center of the tu-
mor. In fact, a knockdown of PLA2 may make cells more sensitive
to hypoxia.
Next I have a general overview question about the interaction
betweenmalignancy and inflammation. Given that this is a secreted
molecule, what do you think about the possibility of transactiva-
tion of malignant cells by inflammatory leukocytes recruited to
the tumor and secreting PLA2?
Dr Yu. Paracrine signaling has been documented by other
groups—sPLA2 group IIa activation of lung macrophages, specif-
ically. So that likely plays a role.
DrWaddell. The specific experimental suggestion I have in this
context is to do mixtures experiments with the tumors or even just
of your transduced tumor cells. If you are looking for an autocrine
inhibitory effect, you might see it if you have a small proportion of
the S2 knockdown cells mixed in with wild-type cells.
Dr Yu. Yes, that is a good idea.
Dr Dao Nguyen (Miami, Fla). I noticed you used 2 cell lines.
The A549 K-Ras mutant and the H358 is p53 mutant and K-Ras
wild type. Is it K-Ras wild-type?
Dr Yu. They are both K-Ras.
Dr Nguyen. My second question is, regarding the reduction of
growth in vivo, can it be because the cells just slow down; they
don’t die at all? So what is your next plan? We want to eradicate
tumors. We don’t want them to slow down.
Dr Yu. Our inhibition experiments have demonstrated an apo-
ptotic response with high concentrations of inhibitor. At a lower
concentration of the inhibitor we see a little bit more of the cell cy-
cle arrest phenomenon. In terms of the mechanisms behind the 2
different responses, I am not exactly sure yet how to explain that.
Dr Nguyen. You saw a reduction in cell proliferation. Did you
look into cell cycle analysis to see if they actually arrest or if they
undergo apoptosis or senescence?
Dr Yu.Our inhibitor experiments looked at that and I have seen
apoptosis and cell cycle arrest. With the knockdown specifically, I
haven’t looked at cell cycle arrest or apoptosis. But like you said,
sPLA2 knockdown did slow tumor growth.diovascular Surgery c Volume 144, Number 5 1191
